Biopharmaceutical business Zafgen has raised $45m in a Series E round to fund the development of its obesity therapeutic beloranib.
New investors RA Capital Management, Brookside Capital, Venrock and Alta Partners backed the round.
The funding round came on the heels of the Phase 2 study of beloranib, which led to significant weight loss and improvements in multiple cardiometabolic risk factors in 147 obese patients.
Atlas Venture partner Peter Barrett said, “Zafgen has continued to attract high quality investors to its syndicate in support of beloranib.”
“Zafgen’s newest investors support some of the most innovative companies and their investment demonstrates confidence in beloranib as a unique pharmacotherapeutic with the potential to address the unmet needs of severely obese patients.”
Back in August this year Brookside and RA participated in a $60m Series C round for pharmaceutical company RNA Interference.
Copyright © 2013 AltAssets